Mario Occhipinti | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer	CLINICAL LUNG CANCER	2022
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers	ESMO OPEN	2022
Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC	FRONTIERS IN IMMUNOLOGY	2022
25P Platinum-based chemotherapy (PCT) addition to first-line PD-1/PD-L1 inhibitors (ICI) prevent hyperprogressive disease (HPD) in non-small cell lung cancer (NSCLC) patients (pts) by reducing circulating immature neutrophils	IMMUNO-ONCOLOGY TECHNOLOGY	2022
Trustworthy artificial intelligence models using real-world and circulating genomics data for the prediction of immunotherapy efficacy in non-small cell lung cancer patients	ANNALS OF ONCOLOGY	2022
KRAS and LKB1 mutation conferring prognostic and predictive role on liquid biopsy in advanced NSCLC	ANNALS OF ONCOLOGY	2022
Baseline circulating immature neutrophils anticipate hyperprogressive disease (HPD) upon 1st-line PD-1/PD-L1 inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients (pts) and are reduced by platinum-based chemotherapy (PCT) and ICI combinations	ANNALS OF ONCOLOGY	2022
Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with novel actionable oncogenic driver alterations	ANNALS OF ONCOLOGY	2022
DNA damage response and repair (DDR) gene mutations as an alternative mechanism to generate high TMB in never smoker NSCLC patients	ANNALS OF ONCOLOGY	2022
EP08.01-006 Using Real World data to build effective predictive machine learining models for NSCLC patients treated with immune-based therapy	JOURNAL OF THORACIC ONCOLOGY	2022
P1.15-02 Plasma microRNAs Modulation in Advanced NSCLC Patients Receiving Single Agent Immune Checkpoint Inhibitors	JOURNAL OF THORACIC ONCOLOGY	2022
MA10.07 Phase II Trial of Sunitinib in Patients with Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines - STYLE Trial (NCT03449173)	JOURNAL OF THORACIC ONCOLOGY	2022
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index	EUROPEAN JOURNAL OF CANCER	2021
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: results from the expanded access program	EUROPEAN JOURNAL OF CANCER	2021
Evaluation of drug-drug interactions in EGFR-mutated non-small-cell lung cancer patients during treatment with tyrosine-kinase inhibitors	JOURNAL OF PERSONALIZED MEDICINE	2021
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: a case-control matched analysis from a large multicenter study	THORACIC CANCER	2021
Immunometabolism of circulating neutrophils in hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) alone or in combination with platinum-based chemotherapy (PCT) in non-small cell lung cancer (NSCLC) patients (pts)	CANCER RESEARCH	2021
Immune-checkpoint inhibitors in advanced non-small cell lung cancer with uncommon histology	CLINICAL LUNG CANCER	2021
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation	CANCER IMMUNOLOGY, IMMUNOTHERAPY	2021
P40.08 Bone-Targeted Agents Improve Survival in High Bone Tumor Burden Advanced Non-Small-Cell-Lung Cancer Patients Treated With PD-(L)1 Inhibitors	JOURNAL OF THORACIC ONCOLOGY	2021